🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Niamh Coleman

Trinity College

ORCID: 0000-0002-5803-9528

Also affiliated with Trinity College Dublin, St. James's Hospital, Geisinger Commonwealth School of Medicine

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies”.

Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Cancer Research Communications(2023)10.1158/2767-9764.crc-22-0260

N/A

0.943DataRank · unranked

37 citations

Niamh Coleman, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Filip Jankú, Jordi Rodón +13 more

Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors

Cancer Medicine(2024)10.1002/cam4.6877

N/A

0.418DataRank · unranked

8 citations

Bettzy Stephen, Siqing Fu, Daniel D. Karp, Vivek Subbiah, Jordi Rodon Ahnert +8 more

Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine

Pharmacogenomics and Personalized Medicine(2021)10.2147/pgpm.s305068

N/A

0DataRank · unranked

56 citations

Justin T. Moyers, Alice Harbery, Igor Vivanco, Timothy A. Yap, Niamh Coleman

Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3108

N/A

0DataRank · unranked

3 citations

Zihan Wei, David S. Hong, Edith P. Mitchell, James A. Zwiebel, Elad Sharon +15 more

Disparities in dosing, drug reduction, and drug discontinuation among US FDA approved tyrosine kinase inhibitors

F1000Research(2023)10.12688/f1000research.124601.1

N/A

0DataRank · unranked

0 citations

Niamh Coleman, Clark R. Andersen, Ying Yuan, Vivek Subbiah, Neha K. Reddy